Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: Yahoo! Finance
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033. The growth is driven by the global rise in chronic diseases such as different types of cancer, autoimmune diseases, and infections. Cancer, particularly is becoming more prevalent among people globally. The American Cancer Society recently released its 2024 Global Cancer Statistics report, which highlights the increasing burden of cancer worldwide. In 2022 alone, approximately 20 million new cancer cases were diagnosed, and 9.7 million people died from the disease. By 2050, annual cancer cases are expected to reach 35 million, driving demand for innovative treatments like immunotherapy. Immunotherapy offers a promising alternative to traditional therapies, and its applications are expanding as research advances. It can be applied to various types of cancer, either alone or alongside treatments like chemotherapy. Immunomodulating agents, a type o
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $675.00 price target on the stock, up previously from $646.00.MarketBeat
- argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Evercore ISI from $675.00 to $706.00. They now have an "outperform" rating on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $617.00 price target on the stock.MarketBeat
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesGlobeNewswire
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.MarketBeat
ARGX
Earnings
- 10/31/24 - Beat
ARGX
Sec Filings
- 11/20/24 - Form 6-K
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- ARGX's page on the SEC website